Compare HNVR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HNVR | MOLN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 143.3M |
| IPO Year | 2022 | 2021 |
| Metric | HNVR | MOLN |
|---|---|---|
| Price | $23.20 | $3.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $24.50 | $8.38 |
| AVG Volume (30 Days) | ★ 75.5K | 6.1K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | $374.07 |
| P/E Ratio | $93.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $3.41 |
| 52 Week High | $24.55 | $5.36 |
| Indicator | HNVR | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 47.83 |
| Support Level | $21.89 | $3.61 |
| Resistance Level | $24.34 | $4.01 |
| Average True Range (ATR) | 0.76 | 0.12 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 32.89 | 38.75 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.